Organon (OGN) Return on Capital Employed (2021 - 2026)
Organon (OGN) posted quarterly Return on Capital Employed of 10.8% for Q1 2026, down 179.0% year-over-year from 13.68% in Q1 2025, and up 3.35% on a QoQ basis from 10.45% in Q4 2025.
Organon (OGN) Return on Capital Employed (2021 - 2026) Analysis & Trends
Organon (OGN) has reported Return on Capital Employed for 6 consecutive years, with 10.8% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed fell 179.0% year-over-year to 10.8%; the TTM figure through Mar 2026 stood at 10.8% (down 179.0% YoY), while the FY2025 annual figure was 10.68%, up 896.0% from the prior year.
- Return on Capital Employed came in at 10.8% for Q1 2026 at Organon, up from 10.45% in the prior quarter.
- The five-year high for Return on Capital Employed was 12.59% in Q1 2025, with the low at 21.38% in Q4 2023.
- Average Return on Capital Employed over 5 years is 5.71%, with a median of 12.22% recorded in 2022.
- Across the five-year window, Return on Capital Employed slumped 1308 bps in 2022 and soared 3302 bps in 2025, its largest moves.
- Year by year, Return on Capital Employed stood at 14.32% in 2022, then plunged by 49 bps to 21.38% in 2023, then surged by 130 bps to 6.43% in 2024, then soared by 63 bps to 10.45% in 2025, then grew by 3 bps to 10.8% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 10.8%, 10.45%, and 11.15% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 42.94% |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 28.18% |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 16.47% |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 9.76% |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -5.22% |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 15.87% |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 21.53% |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -10.20% |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Organon | 3.53 Bn | 2.41 Bn | 783.00 Mn | 10.80% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.80% |
| Dec 31, 2025 | 10.45% |
| Sep 30, 2025 | 11.15% |
| Jun 30, 2025 | 11.98% |
| Mar 31, 2025 | 12.59% |
| Dec 31, 2024 | 6.43% |
| Sep 30, 2024 | -2.18% |
| Jun 30, 2024 | -12.45% |
| Mar 31, 2024 | -20.43% |
| Dec 31, 2023 | -21.38% |
| Sep 30, 2023 | -20.53% |
| Jun 30, 2023 | -17.48% |
| Mar 31, 2023 | -16.42% |
| Dec 31, 2022 | -14.32% |
| Sep 30, 2022 | -12.83% |
| Jun 30, 2022 | -12.22% |
| Mar 31, 2022 | -10.18% |
| Dec 31, 2021 | -10.14% |
| Sep 30, 2021 | -6.89% |
| Jun 30, 2021 | -2.53% |